Combination therapy consisting of an anti-angiogenesis drug and an EGFR-TKI increased the incidence of adverse events of any grade compared with EGFR-TKI therapy alone, especially proteinuria (21.7%), hypertension (18.3%), and bleeding (11.7%), consistent with previous real-world studies [17, 21]. Here, EGFR is linked to hypertensive disorder.